US 12,419,899 B2
Ion channel prosthetic compositions comprising lipid-coated crystals of amphotericin B
Martin D. Burke, Champaign, IL (US); Agnieszka Lewandowska, Savoy, IL (US); Corinne Soutar, Urbana, IL (US); Jeffry G. Weers, Half Moon Bay, CA (US); Thomas Tarara, Burlingame, CA (US); and Danforth P. Miller, San Carlos, CA (US)
Assigned to The Board of Trustees of the University of Illinois, Urbana, IL (US); and cystetic Medicines, Inc., San Carlos, CA (US)
Filed by The Board of Trustees of the University of Illinois, Urbana, IL (US); and cystetic Medicines, Inc., San Carlos, CA (US)
Filed on Sep. 20, 2024, as Appl. No. 18/891,739.
Application 18/891,739 is a continuation of application No. PCT/US2023/015762, filed on Mar. 21, 2023.
Claims priority of provisional application 63/321,965, filed on Mar. 21, 2022.
Prior Publication US 2025/0009776 A1, Jan. 9, 2025
Int. Cl. A61K 31/7048 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 9/16 (2006.01)
CPC A61K 31/7048 (2013.01) [A61K 9/0075 (2013.01); A61K 9/127 (2013.01); A61K 9/1611 (2013.01); A61K 9/1617 (2013.01); A61K 9/1682 (2013.01)] 26 Claims
OG exemplary drawing
 
1. A pharmaceutical composition, comprising:
(i) amphotericin B (AmB), or a pharmaceutically acceptable salt or hydrate thereof;
(ii) cholesterol (Chol);
(iii) phospholipids, comprising hydrogenated soy phosphatidylcholine (HSPC) and distearoylphosphatidylglycerol (DSPG); and
(iv) calcium chloride (CaCl2);
wherein:
the AmB and Chol are not complexed; the AmB is not encapsulated in liposomes; and
the pharmaceutical composition is formulated as a dry powder.